Castillo MI, Ribate VE, Muñoz CM, Santillana SG, Taboada SE, Casterá ME, Abinzano CMJ, Barranco IA, Nieto CR, Pampliega VM, Blanco ML, de Andrés ÁS, de Oteyza PJ, del Castillo BT, Font GI, Cayuela JA, Díez‐Campelo M, Sánchez AR, Vercet SC, Díaz TM. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Cancer Med 2023;
12:16788-16792. [PMID:
37403747 PMCID:
PMC10501246 DOI:
10.1002/cam4.6300]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Revised: 04/11/2023] [Accepted: 06/10/2023] [Indexed: 07/06/2023] Open
Abstract
BACKGROUND
In myelodysplastic neoplasms (MDS), the 20q deletion [del(20q)] is a recurrent chromosomal abnormality that it has a high co-occurrence with U2AF1 mutations. Nevertheless, the prognostic impact of U2AF1 in these MDS patients is uncertain and the possible clinical and/or prognostic differences between the mutation type and the mutational burden are also unknown.
METHODS
Our study analyzes different molecular variables in 100 MDS patients with isolated del(20q).
RESULTS & CONCLUSIONS
We describe the high incidence and negative prognostic impact of U2AF1 mutations and other alterations such as in ASXL1 gene to identify prognostic markers that would benefit patients to receive earlier treatment.
Collapse